Literature DB >> 17567670

Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis.

A Tremblay1, C Mason, G Michaud.   

Abstract

The aim of the present study was to examine the effectiveness of tunnelled pleural catheters (TPC) in patients with malignant pleural effusions who would otherwise be candidates for pleurodesis. Patients were selected from a previously reported database of 250 TPC insertions. The study group was selected based on lung re-expansion and survival as a surrogate maker of eligibility for pleurodesis procedure, as defined by survival of > or =90 days and lung re-expansion > or =80% post-drainage on a standard chest radiograph 2 weeks post TPC placement. There were 109 procedures in 97 patients that met the entry criteria. Spontaneous pleurodesis (SP) was achieved following 70% of procedures and correlated with symptom control. The mean time to SP was 90 days. There was no need for a repeat procedure in 87% of cases overall and in 92% of patients experiencing SP. There were few complications and no procedure-related deaths. Tunnelled pleural catheters are an effective way of controlling malignant pleural effusions when used as first-line treatment in patients who appear to be candidates for pleurodesis procedures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567670     DOI: 10.1183/09031936.00164706

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.

Authors:  Rajesh Thomas; Edward T H Fysh; Nicola A Smith; Pyng Lee; Benjamin C H Kwan; Elaine Yap; Fiona C Horwood; Francesco Piccolo; David C L Lam; Luke A Garske; Ranjan Shrestha; Christopher Kosky; Catherine A Read; Kevin Murray; Y C Gary Lee
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

Review 3.  Palliative care in lung cancer.

Authors:  Betty Ferrell; Marianna Koczywas; Fred Grannis; Annie Harrington
Journal:  Surg Clin North Am       Date:  2011-04       Impact factor: 2.741

Review 4.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

5.  Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion.

Authors:  Mingchen Ba; Hui Long; Yuandong Wang; Yunqiang Tang; Yinbing Wu; Xiangliang Zhang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

Review 6.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.

Authors:  Aaron M Olden; Robert Holloway
Journal:  J Palliat Med       Date:  2010-01       Impact factor: 2.947

8.  Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis.

Authors:  Nadim Srour; Kayvan Amjadi; Alan Forster; Shawn Aaron
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

Review 9.  Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions.

Authors:  Marc Fortin; Alain Tremblay
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 10.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.